Assessment of gadobenate dimeglumine for magnetic resonance angiography: Phase I studies

Investigative Radiology

Volumn 37, Issue 12, 2002, Pages 706-715

  Knopp, M V ^a,b   Schoenberg, S O ^b   Rehm, C ^b   Floemer, F ^b   Von Tengg Kobligk, H ^a,b   Bock, M ^b   Hentrich, H R ^c  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c ALTANA PHARMA AG   (Germany)

Author keywords

Comparative studies; Contrast media; Gd BOPTA; Intraindividual; MR angiography; Phase I studies

Indexed keywords

GADOBENATE DIMEGLUMINE; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE;

ABDOMINAL AORTA; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FLOW RATE; HUMAN; HUMAN EXPERIMENT; IMAGE QUALITY; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIGNAL NOISE RATIO;

EID: 0036895803     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004424-200212000-00011     Document Type: Article

References (32)

1. Debatin JF, Hany TF. MR-based assessment of vascular morphology and function. Eur Radiol 1998;8:528-539.
2. Boos M, Lentschig M, Scheffler K, et al. Contrast-enhanced magnetic resonance angiography of peripheral vessels. Different contrast agent applications and sequence strategies: A review. Invest Radiol 1998;33:538-546.
3. Kauczor HU. Contrast-enhanced magnetic resonance angiography of the pulmonary vasculature. A review. Invest Radiol 1998;33:606-617.
4. Leung DA, McKinnon GC, Davis CP, et al. Breath-hold, contrast-enhanced, three-dimensional MR angiography. Radiology 1996;200:569-571.
5. Prince MR, Narasimham DL, Stanley JC, et al. Breath-hold gadolinium-enhanced MR angiography of the abdominal aorta and its major branches. Radiology 1995;197:785-792.
6. Knopp MV, von Tengg-Kobligk H, Floemer F, et al. Contrast agents for MRA: Future directions. J Magn Reson Imaging 1999;10:314-316.
7. Kirchin MA, Pirovano GP, Spinazzi A. Gadobenate dimeglumine (Gd-BOPTA). An overview. Invest Radiol 1998;33:798-809.
8. de Haen C, Cabrini M, Akhnana L, et al. Gadobenate dimeglumine 0.5 M solution for injection (MultiHance) pharmaceutical formulation and physicochemical properties of a new magnetic resonance imaging contrast medium. J Comput Assist Tomogr 1999;23(Suppl 1):S161-S168.
9. Cavagna FM, Marzola P, Dapra M, et al. Binding of gadobenate dimeglumine to proteins extravasated into interstitial space enhances conspicuity of reperfused infarcts. Invest Radiol 1994;29(Suppl 2):S50-S53.
10. Cavagna FM, Maggioni F, Castelli PM, et al. Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol 1997;32:780-796.
11. Ono S, Kodama Y, Nagao T, et al. The quality of conduct in Japanese clinical trials: Deficiencies found in GCP inspections. Control Clin Trials 2002;23:29-41.
12. CPMP ICH. Guideline for Good Clinical Practice. European Committee for Proprietary Medicinal Products 1996. Available at: http://dg3.eudra.org/F2/eudralex/vol-3/pdfs-en/3cclaen.pdf.
13. Koch GG, Tangen CM, Jung JW. et al. Issues for covariance analysis of dichotomous and ordered categorical data from randomized clinical trials and non-parametric strategies for addressing them. Stat Med 1998;17:1863-1892.
14. Carroll TJ, Korosec FR, Swan JS, et al. The effect of injection rate on time-resolved contrast-enhanced peripheral MRA. J Magn Reson Imaging 2001;14:401-410.
15. Boos M, Scheffler K, Haselhorst R, et al. Arterial first pass gadolinium-CM dynamics as a function of several intravenous saline flush and Gd volumes. J Magn Reson Imaging 2001:13:568-576.
16. Boeve WJ, Sluiter WJ, Kamman RL. Optimization of scan timing in abdominal breath hold contrast-enhanced MRA: An empirical guideline. Magn Reson Imaging 2001;19:193-200.
17. Schoenberg SO, Bock M, Knopp MV, et al. Renal arteries: Optimization of three-dimensional gadolinium-enhanced MR angiography with bolus-timing-independent fast multiphase acquisition in a single breath hold [see comments]. Radiology 1999;211:667-679.
18. Schoenberg SO, Knopp MV, Prince MR, et al. Arterial-phase three-dimensional gadolinium magnetic resonance angiography of the renal arteries. Strategies for timing and contrast media injection: Original investigation. Invest Radiol 1998;33:506-514.
19. Mistretta CA, Grist TM, Korosec FR. et al. 3D time-resolved contrast-enhanced MR DSA: Advantages and tradeoffs. Magn Reson Med 1998;40:571-581.
20. Ho VB, Foo TK. Optimization of gadolinium-enhanced magnetic resonance angiography using an automated bolus-detection algorithm (MR SmartPrep). Original investigation. Invest Radiol 1998; 33:515-523.
21. Fain SB, King BF, Breen JF, et al. High-spatial-resolution contrast-enhanced MR angiography of the renal arteries: A prospective comparison with digital subtraction angiography. Radiology 2001; 218:481-490.
22. Runge VM, Parker JR, Donovan M. Double-blind, efficacy evaluation of gadobenate dimeglumine, a gadolinium chelate with enhanced relaxivity, in malignant lesions of the brain. Invest Radiol 2002;37:269-280.
23. Runge VM, Knopp MV. Off-label use and reimbursement of contrast media in MR. J Magn Reson Imaging 1999;10:489-495.
24. Svensson J, Petersson JS, Stahlberg F, et al. Image artifacts due to a time-varying contrast medium concentration in 3D contrast-enhanced MRA. J Magn Reson Imaging 1999;10:919-928.
25. Kopka L, Vosshenrich R, Rodenwaldt J, et al. Differences in injection rates on contrast-enhanced breath-hold three-dimensional MR angiography. AJR Am J Roentgenol 1998;170:345-348.
26. Hany TF, McKinnon GC, Leung DA, et al. Optimization of contrast timing for breath-hold three-dimensional MR angiography. J Magn Reson Imaging 1997;7:551-556.
27. Earls JP, Rofsky NM, DeCorato DR, et al. Breath-hold single-dose gadolinium-enhanced three-dimensional MR aortography: Usefulness of a timing examination and MR power injector. Radiology 1996;201:705-710.
28. Spinazzi A, Lorusso V, Pirovano G, et al. Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: Results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers. Acad Radiol 1999;6: 282-291.
29. Walsh EG, Anayiotos A, Doyle M, et al. Effect of contrast agent viscosity and injection flow velocity on bolus injection pressures for peripheral venous injection in first-pass myocardial perfusion studies. Technol Health Care 2002:10:57-63.
30. Goyen M, Herborn CU, Lauenstein TC, et al. Optimization of contrast dosage for gadobenate dimeglumine-enhanced high-resolution whole-body 3D magnetic resonance angiography. Invest Radiol 2002;37:263-268.
31. Kirchin MA, Pirovano G, Venetianer C, et al. Safety assessment of gadobenate dimeglumine (MultiHance): Extended clinical experience from phase I studies to post-marketing surveillance. J Magn Reson Imaging 2001;14:281-294.
32. Davies BE, Kirchin MA, Bensel K, et al. Pharmacokinetics and safety of gadobenate dimeglumine (MultiHance) in subjects with impaired liver function. Invest Radiol 2002;37:299-308.